Pharmacological activation of GPX4 by selenomethionine attenuates cisplatin-induced ototoxicity and hearing loss

Key Points

• GPX4 activation leads to a reduction in cisplatin-induced ototoxicity and hearing loss, providing a potential therapeutic strategy.
• Cisplatin exposure was linked to significant ototoxic effects, revealing a critical area for intervention in hearing preservation.
• Observational analysis revealed that selenomethionine effectively activates GPX4 and mitigates damage from cisplatin.
• This approach highlights the potential of using selenomethionine in clinical settings to protect against hearing loss, particularly in patients undergoing chemotherapy.